MX2023005653A - Anticuerpos contra los virus de la influenza a. - Google Patents

Anticuerpos contra los virus de la influenza a.

Info

Publication number
MX2023005653A
MX2023005653A MX2023005653A MX2023005653A MX2023005653A MX 2023005653 A MX2023005653 A MX 2023005653A MX 2023005653 A MX2023005653 A MX 2023005653A MX 2023005653 A MX2023005653 A MX 2023005653A MX 2023005653 A MX2023005653 A MX 2023005653A
Authority
MX
Mexico
Prior art keywords
antigen
viruses
antibodies against
against influenza
polynucleotides
Prior art date
Application number
MX2023005653A
Other languages
English (en)
Inventor
Davide Corti
Elisabetta Cameroni
Gyorgy Snell
Matteo Samuele Pizzuto
Fabrizia Zatta
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of MX2023005653A publication Critical patent/MX2023005653A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente descripción proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que pueden unirse a una hemaglutinina (HA) del virus de la influenza A y pueden neutralizar una infección por IAV. También se proporcionan polinucleótidos que codifican un anticuerpo o fragmento de unión a antígeno, vectores que comprenden tales polinucleótidos, células hospedera que pueden expresar los anticuerpos o fragmentos de unión a antígeno, composiciones relacionadas y métodos para usar las composiciones descritas en el presente documento para, por ejemplo, tratar o prevenir una infección por IAV.
MX2023005653A 2020-11-23 2021-11-19 Anticuerpos contra los virus de la influenza a. MX2023005653A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117437P 2020-11-23 2020-11-23
US202063123419P 2020-12-09 2020-12-09
PCT/US2021/060123 WO2022109291A1 (en) 2020-11-23 2021-11-19 Antibodies against influenza a viruses

Publications (1)

Publication Number Publication Date
MX2023005653A true MX2023005653A (es) 2023-07-31

Family

ID=79021185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005653A MX2023005653A (es) 2020-11-23 2021-11-19 Anticuerpos contra los virus de la influenza a.

Country Status (9)

Country Link
EP (1) EP4247844A1 (es)
JP (1) JP2023551666A (es)
KR (1) KR20230135569A (es)
AU (1) AU2021382620A1 (es)
CA (1) CA3197537A1 (es)
IL (1) IL302938A (es)
MX (1) MX2023005653A (es)
TW (1) TW202235103A (es)
WO (1) WO2022109291A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230448A1 (en) * 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
WO2024081639A1 (en) * 2022-10-11 2024-04-18 Seawolf Therapeutics, Inc. Novel lipid nanoparticle compositions for the delivery of nucleic acids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP3051957B2 (ja) 1997-08-28 2000-06-12 榮太郎 清水 融雪機
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001025454A2 (en) 1999-10-04 2001-04-12 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
CA2540138C (en) 2003-09-24 2013-07-30 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
CA2807664A1 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US8900585B2 (en) * 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
TWI643868B (zh) * 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US9908930B2 (en) * 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN107207611B (zh) * 2015-02-05 2021-11-09 扬森疫苗与预防公司 针对流感血球凝集素的结合分子及其用途
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
BR112020005676A2 (pt) 2017-09-22 2020-10-20 WuXi Biologics Ireland Limited novos complexos polipeptídicos biespecíficos
MA51681A (fr) * 2018-01-26 2021-05-05 Regeneron Pharma Anticorps humains contre l'hémagglutinine de la grippe

Also Published As

Publication number Publication date
CA3197537A1 (en) 2022-05-27
TW202235103A (zh) 2022-09-16
IL302938A (en) 2023-07-01
AU2021382620A1 (en) 2023-06-15
WO2022109291A1 (en) 2022-05-27
KR20230135569A (ko) 2023-09-25
AU2021382620A9 (en) 2024-04-18
JP2023551666A (ja) 2023-12-12
EP4247844A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
MX2020007888A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
MX2023005653A (es) Anticuerpos contra los virus de la influenza a.
MX2022010537A (es) Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
MY194997A (en) Anti-ccr7 antibody drug conjugates
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
MX2022014598A (es) Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
PH12016501444A1 (en) Antibodies against f glycoprotein of hendra and nipah viruses
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
MX2021012962A (es) Anticuerpo monoclonal que se une especificamente a gitr.
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2021005323A (es) Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn.
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2023005654A (es) Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza.
WO2023230445A3 (en) Broadly neutralizing antibodies against influenza neuraminidase
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
BR112021022089A2 (pt) Materiais e métodos para modulação da imunidade mediada por células t
MX2022007207A (es) Composiciones y metodos para tratar y prevenir la influenza.
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
WO2021067714A3 (en) Methods for determining antibody affinity and binding kinetics using vlps or live viruses attached to biosensors